Market closed
Checkpoint Therapeutics, Inc./$CKPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Checkpoint Therapeutics, Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Ticker
$CKPT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
24
ISIN
US1628282063
Website
CKPT Metrics
BasicAdvanced
$348M
-
-$1.22
-
-
Price and volume
Market cap
$348M
52-week high
$4.18
52-week low
$2.37
Average daily volume
1.5M
Financial strength
Current ratio
1.912
Quick ratio
1.849
Management effectiveness
Return on assets (TTM)
-152.73%
Return on equity (TTM)
-1,869.55%
Valuation
Price to revenue (TTM)
4,699.887
Price to book
21.15
Price to tangible book (TTM)
21.15
Growth
Revenue change (TTM)
-39.71%
Earnings per share change (TTM)
-16.59%
3-year revenue growth (CAGR)
-45.41%
3-year earnings per share growth (CAGR)
-45.07%
CKPT News
AllArticlesVideos
Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
GlobeNewsWire·3 days ago
CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT
Business Wire·2 weeks ago
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Checkpoint Therapeutics, Inc. stock?
Checkpoint Therapeutics, Inc. (CKPT) has a market cap of $348M as of May 16, 2025.
What is the P/E ratio for Checkpoint Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Checkpoint Therapeutics, Inc. (CKPT) stock is 0 as of May 16, 2025.
Does Checkpoint Therapeutics, Inc. stock pay dividends?
No, Checkpoint Therapeutics, Inc. (CKPT) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Checkpoint Therapeutics, Inc. dividend payment date?
Checkpoint Therapeutics, Inc. (CKPT) stock does not pay dividends to its shareholders.
What is the beta indicator for Checkpoint Therapeutics, Inc.?
Checkpoint Therapeutics, Inc. (CKPT) does not currently have a Beta indicator.